Latest Lead News

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Sunshine Metals Ltd reports a substantial upgrade to its Ravenswood Consolidated Project, with a 57% rise in contained gold and positive drilling and metallurgical results underpinning the growth.

Vulcan Energy has marked a pivotal quarter with major capital raises, strategic partnerships, and the commencement of Europe’s first fully integrated battery-quality lithium hydroxide production.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Mach7 Technologies reports a robust Q2 FY25 with a 15.6% increase in Contracted Annual Recurring Revenue, reaffirming its FY25 growth guidance and initiating a $5 million share buy-back.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Apollo Minerals reports exceptional drilling results at its Salanie Gold Project in Gabon, revealing high-grade gold mineralisation and securing $1.25 million through a recent entitlement offer.

Frontier Digital Ventures posts a mixed fourth quarter with overall revenue growth but EBITDA pressures, while advancing a strategic review focused on unlocking shareholder value.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.